The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer

Breast cancer is the most common malignancy predominantly affecting women. To date, numerous numbers of studies were reported novel genetic contributors with diagnostic, prognostic, and therapeutic potential for the breast carcinogenesis. However, the role of urotensin-II in breast carcinogenesis ha...

Full description

Saved in:
Bibliographic Details
Published in:Tumor biology 2015-06, Vol.36 (6), p.4427-4432
Main Authors: Yumrutas, Onder, Oztuzcu, Serdar, Büyükhatipoglu, Hakan, Bozgeyik, Ibrahim, Bozgeyik, Esra, Igci, Yusuf Ziya, Bagis, Haydar, Cevik, M. Ozgur, Kalender, M. Emin, Eslik, Zeynep, Arslan, Ahmet
Format: Article
Language:English
Subjects:
Adult
Biomedical and Life Sciences
Biomedicine
Breast cancer
Breast Neoplasms - blood
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer Research
Carcinogenesis - genetics
Cell growth
Enzyme-Linked Immunosorbent Assay
Female
Genetic Association Studies
Genetic Predisposition to Disease
Humans
Middle Aged
Peptides
Plasma
Polymorphism
Research Article
Risk Factors
Urotensins - blood
Urotensins - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Breast cancer is the most common malignancy predominantly affecting women. To date, numerous numbers of studies were reported novel genetic contributors with diagnostic, prognostic, and therapeutic potential for the breast carcinogenesis. However, the role of urotensin-II in breast carcinogenesis has not been elucidated yet. Urotensin-II is a somatostatin-like cyclic tiny peptide identified by its potent vasoconstrictor activity. Soon after its discovery, its involvement in many disease states as well as its expression in various tissues including the tumors have been demonstrated. Moreover, there is strong evidence that suggest urotensin-II as the significant contributor of angiogenesis as well as cell proliferation and tumor biology. In this study, enzyme-linked immunosorbent assay (ELISA) and restriction fragment length polymorphism analysis were used to evaluate plasma levels of urotensin-II and Thr21Met and Ser89Asn polymorphisms of UTS2 gene in breast cancer patients. In the present case-control study, we noticed a significant decrease in the levels of urotensin-II protein in the plasma of the breast cancer patients ( p  
ISSN:1010-4283
1423-0380
DOI:10.1007/s13277-015-3082-2